Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

Plain-language summary

This is a multicenter cohort study examining the microbiome and host susceptibility in patients with severe pneumonia using metagenomic gene sequencing. Patients with a new lung infection requiring mechanical ventilation or high-flow oxygen therapy for acute respiratory failure can take part. It has no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

First Affiliated Hospital of Zhejiang University

Intervention

Metagenomics

Start date

9/25/2023

Estimated completion

12/31/2026

Countries

China

Related genes

Locations

• Hangzhou, China
• Hangzhou, China
• Hangzhou, China
• Hangzhou, China
• Huzhou, China
• Jiaxing, China
• Lanxi, China
• Lishui, China
• Pinghu, China
• Taizhou, China
• Wenzhou, China
• Xi'an, China
• Zhengzhou, China
• Zhengzhou, China
• Zhengzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1\. New lung infection that meets one of the following definitions: the patient receives mechanical ventilation (invasive or non-invasive) due to acute respiratory failure, with a PEEP level of 5cm or above; Patients receiving high flow oxygen therapy with a FiO2 of 50% or more and a PaO2: FiO2 ratio below 300

Exclusion Criteria:

1. Expected length of stay in ICU is less than 1 day
2. Pregnant